Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TSC2 Q1178* |
Therapy | Everolimus |
Indication/Tumor Type | thyroid cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TSC2 Q1178* | thyroid cancer | predicted - sensitive | Everolimus | Case Reports/Case Series | Actionable | In a clinical case study, a thyroid cancer patient harboring TSC2 Q1178* demonstrated an 18-month response to Afinitor (everolimus) (PMID: 25295501; NCT00936858). | 25295501 |
PubMed Id | Reference Title | Details |
---|---|---|
(25295501) | Response and acquired resistance to everolimus in anaplastic thyroid cancer. | Full reference... |